Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed and dated a consent form and a HIPAA privacy form
- Men aged 18 years or older
- People with a confirmed diagnosis of prostate cancer that is Grade Group 3 to 5 (a higher-risk grade) or has spread beyond the prostate, OR has spread into the outer layer of the prostate or nearby seminal vesicles, OR has 3 or more biopsy tissue samples showing higher-grade cancer, OR is suspected to have spread to nearby lymph nodes (based on clinical assessment, MRI, or a special type of scan called a PSMA PET scan)
- People who are scheduled to have a robotic prostate removal surgery and lymph node removal as part of their standard care
- People who are able to understand the study requirements and agree to follow the study rules and attend all required appointments
- People who agree to use an approved method of contraception or abstain from sex for the duration of the study and for 6 weeks after receiving the study drug, and to avoid sperm donation during the study and for 3 months after receiving the study drug (female partners must also use hormonal or barrier contraception unless postmenopausal or abstinent)
Who may not be able to join:
- People whose surgeon plans to use a specific surgical approach called the extraperitoneal approach
- People who have previously had a severe allergic (anaphylactic) reaction to products containing indocyanine green (a type of medical dye)
- People who have a known allergy to any ingredient in the study drug ZOPOCIANINE, including certain chemical components (confirm with trial site for full details)
- People whose kidneys or liver are not functioning well enough — specifically, those with a kidney filtration rate below 50 mL/min, or certain elevated liver test results above defined thresholds (confirm with trial site)
- People who have an abnormal heart rhythm measurement (called a QTc interval of 470 milliseconds or more) on a heart tracing test (ECG) done at screening
- People with a significant ongoing or recent serious medical, neurological, or other health condition that, in the lead doctor's opinion, could affect their safety, their ability to complete the study, or the study's results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clint Bahler, MD, Indiana University
Phone: 317-948-9575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Porportion of subjects who have a Clinically Significant Event
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.